• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Karyopharm - oncology

























































Looks like Wall Street agrees that our company and our drug is a joke with little future upside. We are literally back to where we started over 2 1/2 years ago from a share price perspective. Time to start looking...the HOS' and RBD's who left early are looking like geniuses right about now.
 




















Gee, does this mean that Ricky’s brilliance won’t deliver the goods?


Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Simply Wall St News

https://simplywall.st/stocks/us/pha...ts-just-became-more-bearish-on-karyopharm-the

Market forces rained on the parade of Karyopharm Therapeutics Inc.(NASDAQ:KPTI) shareholders today, when the analysts downgraded their forecasts for this year. Revenue estimates were cut sharply as analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well.

Following the downgrade, the consensus from nine analysts covering Karyopharm Therapeutics is for revenues of US$99m in 2021, implying a perceptible 3.7% decline in sales compared to the last 12 months. Losses are forecast to hold steady at around US$2.80. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$119m and losses of US$2.82 per share in 2021. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers.